Exclusion criteria were explicitly stated in almost all studies (11 out of 12), with common criteria including previous growth hormone (GH) therapy [15,19,20,22,24,26,27], age over 15 years at the initiation of biologic treatments [15], advanced puberty [20], postpubertal patients at biologic therapy onset [22], major concurrent medical conditions [13,21,22], and biopsy diagnosis of inflammatory bowel disease [23]. This evidence concerns the gene GH1 and inflammatory bowel disease.